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Results of electrophysiologic testing and 
long-term prognosis in patients with coronary 
artery disease and aborted sudden death 
The purpose of this study was to evaluate the results of electrophysiologic testing and the 
long-term prognosis of 56 patients with coronary artery disease who presented with aborted 
sudden death unrelated to acute myocardial infarction. The mean age of the patients was 62 + 6 
years (2 standard deviation) and 46 were men. The mean left ventricular ejection fraction was 
0.34 i 0.16. During the baseline electrophysiology test, sustained monomorphic ventricular 
tachycardia (VT) was inducible in 22 patients who then underwent electropharmacologic testing: 
11 patients were treated with antiarrhythmic drugs that suppressed the induction of VT or 
resulted in the VT becoming hemodynamically stable; 10 patients who failed drug testing 
received an automatic implantable cardioverter/deflbrlllator (AICD); one patient underwent 
endocardlal resection. Among 34 patients who did not have inducible sustained VT, a precipitant 
of cardiac arrest (severe ischemla, proarrhythmia) was identified and was corrected in 9 of 34. 
An AICD was recommended in the remaining 25 patients; however, nine patients refused and 
were treated empirically with antiarrhythmic drugs. The mean follow-up was 22 +- 12 months. The 
P-year actuarial incidence of sudden death was 31% in patients who were treated with drugs 
based on the results of electropharmacologic testing, 26% in patients who were treated with 
antiarrhythmic drugs on an empiric basis, 0% among patients in whom a correctable etiology for 
the cardiac arrest was identified, and 9% among patients who underwent implantation of an 
AICD. The 3-year actuarial incidence of sudden death among the 20 patients treated with 
antiarrhythmic drugs was 53%, compared with 9% among the 26 patients who underwent AICD 
implantation (p = 0.03). In conclusion, antiarrhythmic therapy, whether guided by 
electrophysiologic testing or administered on an empiric basis, is associated with a high 
incidence of recurrent sudden death in patients with coronary artery disease and aborted sudden 
death. Implantation of an AICD may be advisable in all patients with coronary artery disease and 
aborted sudden death in whom a correctable precipitant cannot be identified. (AM HEART J 
1991;122:1001.) 
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Although several previous studies have described the 
results of electrophysiologic testing and the progno- 
sis in patients with aborted sudden death, many of 
these studiesle5 have included heterogeneous patient 
populations with various types of heart disease and 
the majority were performed before the widespread 
availability of the automatic implantable cardiovert- 
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er/defibrillator (AICD). Several issues relevant spe- 
cifically to patients with coronary artery disease re- 
main to be clarified. 
The purpose of this study was to address the fol- 
lowing questions in patients with coronary artery 
disease and a recent history of aborted sudden death: 
(1) How often is an adequate response to electro- 
pharmacologic testing obtained in patients with 
inducible, sustained monomorphic ventricular ta- 
chycardia (VT)? (2) How often can a potentially re- 
versible etiology for the cardiac arrest be identified in 
patients without inducible VT? (3) How does long- 
term prognosis relate to the inducibility of VT, to a 
response to drug-testing, to treatment with coronary 
revascularization in patients without inducible VT, 
and to the use of the AICD? 
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Table I. Comparison of patients with and without inducible 
sustained monomorphic ventricular tachycardia 
Clinical SMVT 








No. of obstructed CAs 
62 k 8* 62 t 8 
2012 2816 
19 (86%) 26 (76%) 
5 6 
15 (68%) 11 (32%) 
19 (86%) 18 (53%) 
0.30 r 0.15 0.38 + 0.16 
2.5 + 0.75 2.0 f 0.8 
Without 
SMVT 









CA, Coronary artery; CHF, congestive heart failure; LVEF, left ventricular 
ejection fraction; SMVT, sustained monomorphic ventricular tachycardia. 
*Mean i standard deviation. 
METHODS 
Patient population. The subjects of this study were 56 
consecutive patients with coronary artery disease who were 
referred for evaluation of out-of-hospital aborted sudden 
death unrelated to acute myocardial infarction between 
September 1986 and September 1989. The mean age of 
these patients was 62 of: 8 years (-t- standard deviation), 
and there were 48 men and 8 women. Each patient required 
electrical cardioversion, cardiopulmonary resuscitation, 
and/or direct-current countershock during the cardiac ar- 
rest. Patients with electrocardiographic evidence of a new 
transmural myocardial infarction were excluded from the 
study. A history of previous myocardial infarction was 
present in 45 patients (80%). Eleven patients had under- 
gone previous revascularization procedures (nine with by- 
pass surgery and two with angioplasty). Ten patients were 
taking antiarrhythmic drugs at the time of the cardiac ar- 
rest, including quinidine (four), procainamide (two), dis- 
opyramide, tocainide, mexiletine, or amiodarone. Signs 
and symptoms of congestive heart failure were present in 
37 patients. Fifty-three patients had angiographically- 
proven coronary artery disease. In three patients, each of 
whom had a history of myocardial infarction, coronary an- 
giography was not performed. There were 26 patients with 
three-vessel disease, 15 with two-vessel disease, and 13 with 
one-vessel disease. The mean left ventricular ejection frac- 
tion as determined by a contrast ventriculogram or a radi- 
onuclide angiogram was 0.34 * 0.16. Angiographic evi- 
dence of a left ventricular aneurysm was present in 26 pa- 
tients. 
Electrophysiologic testing. Electrophysiology tests 
were performed in the fasting, unsedated state after 
informed consent had been obtained from each patient. 
The electrophysiology tests were performed at a mean of 
42 + 76 days after the cardiac arrest. All antiarrhythmic 
drugs were discontinued at least 5 half-lives before the test. 
Three quadripolar electrode catheters were inserted into a 
femoral vein and were positioned in the right atrium, His 
bundle, and right ventricle. The surface electrocardio- 
graphic leads and intracardiac electrograms were recorded 
on a Siemens Elema Mingograph 7 recorder (Siemens 
Elema AB, Solna, Sweden). A programmable stimulator 
(Bloom Associates, Ltd., R.eading, Pa.) was used to deliver 
rectangular pulses 2 msec in duration at twice the diastolic 
threshold. Programmed ventricular stimulation was per- 
formed at the right ventricular apex and at the outflow 
tract or septum using one, two, and three extrastimuli de- 
livered after an eight-beat drive train at cycle lengths of 400 
and 600 msec. For each extrastimulus, diastole was scanned 
in 10 msec decrements to the point of ventricular refrac- 
toriness or until a coupling interval of 200 msec was 
attained. If monomorphic VT was not inducible, pro- 
grammed stimulation was repeated during an infusion of 
isoproterenol at a rate of 1 to 4 gg/min titrated to maintain 
a heart rate of 110 to 120 beats/min. 
Sustained VT was defined as VT with a duration > 30 
seconds or requiring termination because of hemodynamic 
collapse. Nonsustained VT was defined as VT having a 
duration of 6 beats to 30 seconds. Induced VT was consid- 
ered monomorphic if the QRS morphology was constant 
and the cycle length was > 200 msec. Polymorphic VT was 
defined as VT that had a variable QRS morphology. Ven- 
tricular fibrillation was defined as an arrhythmia having a 
disorganized QRS morphology and a cycle length < 200 
msec. 
Patient management. All patients who had inducible, 
sustained monomorphic VT underwent serial electrophar- 
macologic testing. Drugs were tested based on each pa- 
tient’s history and previous clinical response. A Class IA or 
IC drug was usually used first, followed by amiodarone, 
then by a combination of amiodarone and a Class I drug. 
The tests were performed after oral loading adequate to 
achieve a steady-state drug level. Patients treated with 
amiodarone were retested after 1 to 2 weeks of loading with 
1.2 to 2.4 gm/day. The dosages of the other drugs were: 
quinidine, 1.2 to 1.6 gmlday; mexiletine, 600 to 900 mglday; 
procainamide, 2 to 3 gmlday; encainide, 105 mglday. The 
response to a drug was considered adequate if sustained VT 
was no longer inducible or, in the case of amiodarone, if only 
relatively slow and hemodynamically stable VT (mean 
blood pressure > 70 mm Hg) was inducible.‘j In patients 
who failed electropharmacologic testing, AICD implanta- 
tion was recommended. 
Electropharmacologic testing was not performed in pa- 
tients who had inducible polymorphic VT or ventricular 
fibrillation (VF), because these arrhythmias are often a 
nonspecific response to programmed stimulation and their 
clinical significance is unclear.Yl * 
In patients in whom monomorphic VT could not be in- 
duced, reversible causes for the cardiac arrest were sought. 
These included proarrhythmia (assumed when the episode 
of cardiac arrest occurred after the initiation of the drug or 
after an increase in dosage of an antiarrhythmic drug 
known to cause serious proarrhythmia) or cardiac ischemia 
(assumed when the cardiac arrest was preceded by angina, 
if coronary angiography demonstrated critical coronary le- 
sions, and if functional studies revealed evidence of is- 
chemia). In these patients, management included discon- 
tinuation of the proarrhythmic drug or myocardial revas- 
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Fig. 1. Management and outcome of patients. Actuarial incidence of sudden death, according to 
treatment. E.P., Electrophysiologic; AICD, automatic implantable cardioverter/defibrillator; Ischem., is- 
chemia; Proarr., proarrhythmia; VT, ventricular tachycardia. 
cularization without implantation of an AICD if the left 
ventricular ejection fraction was > 0.35. In patients who 
had neither inducible VT nor an identifiable reversible 
cause, implantation of an AICD was recommended. If 
AICD implantation was declined, empiric antiarrhythmic 
therapy was initiated. 
All patients were followed on a regular basis by one of the 
investigators or by their referring physicians. To obtain 
follow-up information for this study, patients were inter- 
viewed in person or by telephone. Sudden death was 
defined as unexpected natural death occurring during sleep 
or within 1 hour of the patient’s collapse. In patients who 
had an AICD, the number of shocks was noted. 
Statistical analysis. Continuous data are expressed as 
the mean + 1 standard deviation. Comparisons were per- 
formed using chi square analysis or Student’s t test. Actu- 
arial survival curves were constructed by the Kaplan-Meier 
method and were analyzed with the log-rank test. If death 
was not sudden or there was a change in therapy, the pa- 
tient was censored. Predictors of inducible monomorphic 
VT and recurrent sudden death were evaluated with the 
Cox regression model.g A p value < 0.05 was considered 
significant. 
RESULTS 
Electrophysiologic testing. Sustained monomorphic 
VT was induced by ventricular programmed stimu- 
lation in 22 of 56 patients (40% ). The VT was 
induced by two extrastimuli in nine patients (41% ), 
by three extrastimuli in 11 patients (50 % ), and by 
two extrastimuli during isoproterenol infusion in two 
patients (9% ). The VT cycle length varied between 
210 and 420 msec (mean 273 + 52 msec). The in- 
duced VT had a right bundle branch block morphol- 
ogy in 12 patients and a left bundle branch block 
morphology in 10. Among the 34 patients in whom 
sustained monomorphic VT could not be induced, 
sustained polymorphic VT was induced in two pa- 
tients, ventricular fibrillation was induced in four, 
nonsustained VT was induced in 10 patients (poly- 
morphic in nine and monomorphic in one), and no 
ventricular arrhythmias could be induced in 18 
patients. 
The patients who did and did not have inducible 
sustained, monomorphic VT are compared in Table 
I. Three clinical variables were associated with the 
presence of inducible monomorphic VT: evidence of 
a left ventricular aneurysm (p < O.Ol), the number of 
diseased coronary arteries 0, < 0.03), and evidence of 
heart failure 0, < 0.01). Other clinical variables in- 
cluding age, sex, history of previous myocardial inf- 
arction, left ventricular ejection fraction, previous 
revascularization procedures, and prior antiarrhyth- 
mic drug therapy were similar in the two groups. 
Drug testing and management (Fig. 1). All patients 
in whom sustained monomorphic VT could be in- 
duced underwent serial electropharmacologic testing 
with a mean of 1.8 + 0.8 drugs. Eleven patients 
(50% ) had an adequate response: two with quinidine, 
four with amiodarone, and five with a combination of 
amiodarone and a Class I drug. The patients who 
failed electropharmacologic testing underwent im- 
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Fig. 2. Kaplan-Meier actuarial survival curves of pa- 
tients who had an AICD (n = 26) and of patients who had 
antiarrhythmic drug therapy (n = 20). There was a signif- 
icant difference at 3 years of follow-up 0, = 0.03) between 
the two groups. Patients were censored if death was not 
sudden. 
plantation of an AICD (10 patients) or had endocar- 
dial resection (one patient). Four of these patients 
also underwent bypass surgery. There were no sig- 
nificant differences in clinical or electrophysiologic 
characteristics between the patients who had an ad- 
equate response to electropharmacologic testing and 
those who did not. 
Among the 34 patients without inducible sustained 
monomorphic VT, a correctable factor that was likely 
to be responsible for the cardiac arrest was identified 
in nine patients. Proarrhythmia was presumed to be 
responsible for their cardiac arrest in two patients 
who had been treated with quinidine and who had a 
prolonged QT interval. In seven patients whose mean 
left ventricular ejection fraction was 0.50 + 0.13 
(range 0.35 to 0.69), ischemia was identified as the 
probable precipitant of cardiac arrest; revasculariza- 
tion was performed with bypass surgery in one 
patient and by percutaneous coronary angioplasty in 
six. These patients were also treated on a long-term 
basis with @-adrenergic blocking or calcium antago- 
nist agents. Sixteen other patients without inducible, 
sustained monomorphic VT underwent implantation 
of an AICD (with concomitant bypass surgery in six). 
Nine patients declined AICD implantation and were 
treated empirically with amiodarone, quinidine, 
encainide, or procainamide. 
Long-term follow-up (Fig. 1). The mean duration of 
follow-up was 22 2 12 months. There were a total of 
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15 deaths, with 10 being sudden. The overall actuar- 
ial rate of sudden death was 14 % at 1 and 2 years, and 
30% at 3 years. The actuarial rates of sudden death 
in the various subgroups of patients are shown in Fig. 
1. The incidence of sudden death was not signifi- 
cantly different among these subgroups, except for 
the patients who had a reversible cause of cardiac ar- 
rest, and for those who had a significantly lower in- 
cidence of sudden death at 2 years of follow-up. None 
of the patients had other significant arrhythmic 
events, such as sustained VT not associated with loss 
of consciousness. 
A total of 26 patients underwent AICD implanta- 
tion: 10 with inducible sustained, monomorphic VT 
who failed electropharmacologic testing and 16 with- 
out inducible VT in whom there was no apparent re- 
versible factor for the cardiac arrest. The 3-year in- 
cidence of sudden death was 9 % in these 26 patients, 
compared with 53 % in the 20 patients who received 
antiarrhythmic therapy (p = 0.03) (Fig. 2). Among 
the patients who received an AICD, in those who had 
inducible sustained, monomorphic VT, eight re- 
ceived shocks (80%), while in those without induc- 
ible VT, seven received shocks (44% ). Symptoms of 
cerebral hypoperfusion preceded 80 % of the shocks. 
Statistical analysis failed to show any variable that 
had independent predictive value for sudden death 
in the first 3 years of follow-up among the clinical, 
angiographic, electrophysiologic, and therapeutic 
variables considered. 
DISCUSSION 
Patients with inducible VT. The results of this study 
demonstrate that sustained, monomorphic VT can 
be induced in slightly less than 50 % of patients with 
coronary artery disease following an episode of 
aborted sudden death. The ability to induce sus- 
tained, monomorphic VT correlates with the pres- 
ence of a left ventricular aneurysm, congestive heart 
failure, and triple-vessel disease. Based on electro- 
pharmacologic testing, an “effective” antiarrhythmic 
drug was identified in 50% of these patients. How- 
ever, the results of long-term therapy guided by elec- 
tropharmacologic testing were disappointing, with 
approximately a 50 % incidence of sudden death at 3 
years of follow-up. Patients who failed electrophar- 
macologic testing received an AICD, and although 
the 3-year incidence of sudden death in these pa- 
tients was 11% , the majority experienced at least one 
AICD discharge during follow-up. This suggests that 
the incidence of sudden death in these patients may 
have been considerably higher had an AICD not been 
implanted. 
Patients without inducible VT. Among the 60% of 
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patients in this study who did not have inducible, 
sustained, monomorphic VT, a potentially correct- 
able cause of cardiac arrest, namely ischemia or 
proarrhythmia, could be identified in one fourth. 
These patients, all of whom had left ventricular ejec- 
tion fractions of L 0.35, had an excellent prognosis 
after revascularization or discontinuation of treat- 
ment with the proarrhythmic agent, and therefore it 
appears that specific ant&rhythmic therapy may 
not be necessary if a reversible cause of cardiac arrest 
can be identified and corrected and if the patient does 
not have severe left ventricular dysfunction. 
In the patients who had neither inducible VT nor 
an identifiable precipitant of cardiac arrest, the fac- 
tors that triggered the episode of aborted sudden 
death remain conjectural. Empiric antiarrhythmic 
therapy in these patients was associated with a 63 % 
incidence of sudden death at 3 years of follow-up, 
compared with a 7% 3-year incidence of sudden 
death in comparable patients who received an AICD. 
Furthermore, approximately half of the patients who 
had an AICD experienced one or more AICD dis- 
charges during follow-up, suggesting that the inci- 
dence of sudden death may have been higher than 
7% if an AICD had not been implanted. 
Incidence of inducible VT. The incidence of induc- 
ible VT in patients who have survived an episode of 
out-of-hospital cardiac arrest has been reported to 
vary between 55 % and 81% , depending on the pa- 
tient population, the programmed stimulation pro- 
tocol, and the end points of programmed stimula- 
tion.1-5v lo-l3 The present study differed from these 
prior studies in two ways. First, the subjects of the 
present study were a homogeneous group of patients 
with chronic coronary artery disease and out-of-hos- 
pital cardiac arrest. Second, because the inducibility 
of nonsustained or polymorphic VT/VF is of unclear 
significance and because these arrhythmias may of- 
ten represent a nonspecific response to programmed 
stimulation,7T * only sustained, monomorphic VT was 
considered to be a positive finding during electro- 
physiologic testing. These differences may explain 
why the incidence of inducible VT in the present 
study (40 % ) was lower than the incidence reported in 
several prior studies. 
Unreliability of electropharmacologic testing. In prior 
studies, patients with sustained VT who were treated 
long-term with antiarrhythmic drugs that suppressed 
the induction of VT were found to have a relatively 
good prognosiszW4v 6l l4 However, in the present study, 
there was a 49 % 3-year incidence of sudden death in 
the group of patients whose drug therapy was guided 
by electropharmacologic testing. This suggests that 
therapy based on electropharmacologic testing may 
not be as reliable long-term in patients with coronary 
artery disease who have had aborted sudden death as 
in patients who present with sustained VT. Differ- 
ences in left ventricular function, the susceptibility 
to ischemic events, and changes in the myocardial 
arrhythmia substrate over time may be among the 
factors that could account for the unreliability of 
therapy based on electropharmacologic testing in the 
patients in this study. 
Reversible causes of cardiac arrest. The inability to 
induce sustained, monomorphic VT in a patient with 
coronary artery disease who has survived a cardiac 
arrest may suggest that the anatomic substrate for 
sustained VT is not present and that the cardiac ar- 
rest was precipitated by a reversible abnormality 
such as ischemia, an electrolyte disturbance, or drug 
proarrhythmia. However, among the patients in this 
study in whom VT could not be induced, evidence 
suggestive of a reversible precipitant of cardiac arrest 
was found in only 25 % . As has been reported prev- 
iously,l’ the prognosis of these patients was good with 
therapy directed only at correcting the abnormality 
presumed to have triggered the cardiac arrest, i.e., 
ischemia or proarrhythmia. 
The mechanism of cardiac arrest is unclear in the 
patients who had neither inducible VT nor evidence 
of a precipitant abnormality. Nevertheless, it is clear 
that these patients remain at risk of sudden death 
and that empiric antiarrhythmic drug therapy is in- 
appropriate in these patients, since the incidence of 
sudden death was 63% at 3 years of follow-up when 
patients were treated in this fashion, This high inci- 
dence of sudden death suggests that AICD implan- 
tation may be the optimal therapy in these patients. 
Prognosis after AICD implantation. Among the 26 
patients who underwent implantation of an AICD, 
the incidence of sudden death at 2 years of follow-up 
was 9 % . In contrast, previous studies have reported 
that the e-year incidence of sudden death in patients 
who have received an AICD is < 5% .15-lg This differ- 
ence in survival following AICD implantation may be 
attributable to differences in the patient population 
of various studies. Unlike most prior studies, the 
present study included only patients who had already 
had an episode of out-of-hospital cardiac arrest and 
therefore were at high risk of having a recurrence. 
Despite the significant incidence of sudden death 
following AICD implantation, the fact that a major- 
ity of patients experienced at least one discharge 
from the AICD during follow-up suggests that the 
AICD was probably effective in reducing the inci- 
dence of sudden death. However, it must be acknowl- 
edged that some AICD discharges may not have been 
triggered by life-threatening VT/VF, especially 
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among the 20 % of patients who received a shock that 
was not preceded by any symptoms of cerebral hypo- 
perfusion. A comparison of the incidence of sudden 
death in patients who were treated with an antiar- 
rhythmic drug and in those who received an AICD 
(53 % versus 9% at 3 years of follow-up) indicates 
that the AICD may be the treatment of choice in pa- 
tients similar to the ones in this study. 
Predictive value of the left ventricular ejection frac- 
tion. In accord with their history of cardiac arrest, the 
majority of patients in this study had left ventricular 
dysfunction. Whereas prior studies have demon- 
strated that left ventricular ejection fraction is a sig- 
nificant predictor of sudden death,3, 4 this was not the 
case in the present study. However, the absence of 
any correlation between ejection fraction and sudden 
death in the patients in this study may be explained 
by the fact that all of these patients had already had 
an aborted episode of sudden death before entry into 
the study. Therefore they had already demonstrated 
themselves to be the high-risk patients that other 
studies would have predicted to be at risk. 
Conclusions. Patients who have coronary artery 
disease and who have survived an out-of-hospital 
cardiac arrest remain at high risk of sudden death 
whether or not sustained monomorphic VT can be 
induced during a baseline electrophysiology test, ex- 
cept for the relatively small subgroup of patients in 
whom there is evidence of a correctable precipitant 
such as ischemia or proarrhythmia. Because antiar- 
rhythmic drug therapy, whether guided by electro- 
pharmacologic testing or administered on a empiric 
basis, is associated with a high incidence of sudden 
death, AICD implantation may be advisable in all 
patients with coronary artery disease and aborted 
sudden death in whom a correctable precipitant can- 
not be identified. 
The authors thank Marion Maguire for expert assistance in the 
preparation of the manuscript. 
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